| (Values in U.S. Thousands) | Dec, 2013 | Dec, 2012 | Dec, 2011 | Dec, 2017 | Sep, 2017 |
| Sales | 42,480 | 33,590 | 52,790 | 0 | 0 |
| Sales Growth | +26.47% | -36.37% | unch | unch | unch |
| Net Income | 10,530 | 6,210 | 13,660 | 0 | 0 |
| Net Income Growth | +69.57% | -54.54% | unch | unch | unch |
Skystar Bio-Pharmaceutical CO (SKBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Skystar Bio-pharmaceutical Company is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has grown to become one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Products under development include: Products for animal immunization, New technology based on protein technology and complex enzyme preparations to be used in feed additives and veterinary medicines and New veterinary medicines for domestic pets.
Fiscal Year End Date: 12/31